Currentblue cross blue shield - tennesseePolicy N/A

Oral_Cancer_Screening_And_Testing_Comm_Ma_Bc_Dsnp_G2113

Defines coverage criteria and limitations for oral and oropharyngeal cancer testing, including HPV testing methods that meet coverage and specific tests that do not meet coverage. Lists applicable CPT/HCPCS codes and regulatory disclaimers.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyOral_Cancer_Screening_And_Testing_Comm_Ma_Bc_Dsnp_G2113

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDocument that the individual has oropharyngeal squamous cell carcinoma and that testing is to establish HPV tumor status when ordering high-risk HPV mRNA E6/E7 testing or p16 immunohistochemistry.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes were made in this update.

1Covered Indication (HPV testing to establish tumor status)

4Not Covered Test Types Listed

8Procedure Codes Referenced

Coverage Summary

Payer policy: Oral Cancer Screening and Testing (status: CURRENT). Effective date: not specified in the source. Scope: Defines coverage criteria and limitations for oral and oropharyngeal cancer testing, including applicable CPT/HCPCS procedure codes.

Coverage stance: Mixed. Covered when used to establish HPV tumor status in individuals with oropharyngeal squamous cell carcinoma using high-risk HPV testing by either mRNA E6/E7 expression testing or p16 immunohistochemistry. Tests explicitly listed as not meeting coverage criteria include salivary biomarker testing (peptides/proteins, nucleic acids, metabolites), HPV genotyping (e.g., OraRisk® HPV), gene expression profiling, and panels combining genetic and nongenetic biomarkers (e.g., mRNA CancerDetect™).

Key Facts

Covered Indication (HPV testing to establish tumor status)1

Not Covered Test Types Listed4

Procedure Codes Referenced8

Scope SummaryDefines coverage criteria and limitations for oral and oropharyngeal cancer testing, including HPV testing methods that meet coverage and specific tests that do not meet coverage. Lists applicable CPT/HCPCS codes and regulatory disclaimers.

Medical Necessity / Coverage Criteria

Medically Necessary / Meets Coverage Criteria

Covered when ALL of the following are met:

ALL of the following

Individual has oropharyngeal squamous cell carcinoma
Establishing HPV tumor status applies to individuals with oropharyngeal squamous cell carcinoma
Testing is for high-risk HPV
Acceptable methods: mRNA expression testing for HPV E6/E7 OR immunohistochemistry for p16 expression

Not Medically Necessary / Does Not Meet Coverage Criteria

The following tests DO NOT MEET COVERAGE CRITERIA due to lack of sufficient published evidence:

Any of the following

Salivary biomarker testing (e.g., peptides/proteins, nucleic acids, metabolites).
Genotyping of HPV (e.g., OraRisk® HPV).
Gene expression profiling.
Panels that incorporate genetic risk factors with nongenetic biomarkers (e.g., mRNA CancerDetect ™ ).

Procedure and Test Codes

Referenced Procedure Codesmixed

81599	Unlisted multianalyte assay with algorithmic analysis.
82397	Chemiluminescent assay.
87624	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types.
87625	Infectious agent detection by nucleic acid (DNA or RNA); HPV types 16 and 18 only, includes type 45, if performed.
88341	Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure.
88342	Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure.
0296U	Oncology (oral and/or oropharyngeal cancer), gene expression profiling by RNA sequencing at least 20 molecular features, saliva, algorithm reported as positive or negative for signature associated with malignancy (Proprietary test: mRNA CancerDetect ™ ; Viome Life Sciences, Inc.).
0429U	Human papillomavirus (HPV), oropharyngeal swab, 14 high-risk types (Proprietary test: OmniPathology Oropharyngeal HPV PCR Test; OmniPathology Solutions, Medical Corporation).

Provider Actions & Billing Impact

Documentation Required

Indication documentation for HPV testing

Document that the patient has oropharyngeal squamous cell carcinoma and that the requested testing is intended to establish HPV tumor status when ordering high‑risk HPV mRNA E6/E7 testing or p16 immunohistochemistry. This documentation requirement applies to the listed procedure codes.

87624
87625
88342
88341
0429U

Denial Risk

Tests that will be denied/not meet coverage

Claims for the listed tests do not meet coverage criteria and are subject to denial because these test types lack sufficient published evidence supporting their use for screening, diagnosis, or management of oral/oropharyngeal cancer.

0296U
81599

Background & Definitions

Oral cancer is defined as cancer occurring in the oral cavity between the vermilion border of the lips and the junction of the hard and soft palates or the posterior one third of the tongue; squamous cell carcinoma is the most common type.

Regulatory context: Laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as high-complexity tests; these LDTs are not FDA approved or cleared although FDA clearance/approval is not currently required for clinical use.

Term	Definition
Oral cancer	Cancer occurring in the oral cavity between the vermilion border of the lips and the junction of the hard and soft palates or the posterior one third of the tongue.
LDT	Laboratory-developed test regulated by CMS under CLIA as high-complexity tests; not FDA approved/cleared.